Imatinib Mesylate.

@article{Waller2018ImatinibM,
  title={Imatinib Mesylate.},
  author={Cornelius F Waller},
  journal={Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer},
  year={2018},
  volume={212},
  pages={
          1-27
        }
}
Imatinib mesylate (Gleevec, Glivec [Novartis, Basel, Switzerland], formerly referred to as STI571 or CGP57148B) represents the paradigm of a new class of anticancer agents, so-called small molecules. They have a high selectivity against a specific molecular target known to be the cause for the establishment and maintenance of the malignant phenotype. Imatinib is a rationally designed oral signal transduction inhibitor that specifically targets several protein tyrosine kinases, Abl, Arg (Abl… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

The PDGF/PDGFR pathway as a drug target.

Molecular aspects of medicine • 2018
View 1 Excerpt

Similar Papers

Loading similar papers…